A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF FORMULATION AND TABLET HARDNESS ON THE RELATIVE BIOAVAILABILITY OF PICTILISIB (GDC-0941) IN HEALTHY SUBJECTS
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2016
Price : $35 *
At a glance
- Drugs Pictrelisib (Primary)
- Indications Acute myeloid leukaemia; Breast cancer; Male breast cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Genentech
- 13 May 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 29 Apr 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.
- 25 Mar 2014 New trial record